Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  rilimogene galvacirepvec
Find trials that include:  Any drugs shown
Results 1-6 of 6 for your search:
Start Over
Enzalutamide with or without Vaccine Therapy in Treating Patients with Metastatic Hormone Resistant Prostate Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0146, NCI-2013-01565, 1301-1204, 130146, P121106, RD-13-I-11, NCT01867333
PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients with Localized Prostate Cancer Undergoing Active Surveillance
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: Not specified
Trial IDs: 1410547210, NCI-2014-02556, AZ027, HHSN2612012000311, N01-CN-2012-00031, UAZ2014-03-01, NCT02326805
Docetaxel and PROSTVAC for Metastatic Castration Sensitive Prostate Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0048, NCI-2016-00058, 1511-1478, P152467, RD-15-IX-08, NCT02649855
Rilimogene Galvacirepvec and Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine in Preventing Relapse in Patients with Prostate Cancer after Radical Prostatectomy
Status: Active
Phase: Phase II
Type: Prevention, Treatment
Age: 22 and over
Trial IDs: 102377, NCI-2016-01144, NCT02772562
Rilimogene Galvacirepvec, Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine, and Nivolumab with or without Ipilimumab in Treating Men with Prostate Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17-C-0007, NCI-2016-01566, P162655, NCT02933255
Rilimogene-Galvacirepvec and Prostvac-V/F in Treating Patients with Biochemical Recurrent Prostate Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0035, NCI-2015-02254, 1510-1475, P152347, RD-15-VIII-18, NCT02649439
Start Over